
Loading, please wait...

Loading, please wait...

Deoxynivalenol (DON), frequently referred to as vomitoxin, is a prevalent trichothecene mycotoxin that contaminates cereal-based foods worldwide. This toxin poses a significant threat to intestinal health in both humans and livestock by disrupting the epithelial barrier and triggering inflammation. Recent research has identified that glucuronolactone intestinal injury protection offers a promising nutritional strategy to mitigate these harmful effects.
Glucuronolactone (GLU) effectively alleviates the damage caused by DON through a multifaceted mechanism that centers on the intestinal mucus barrier. Specifically, GLU promotes mucin sulfation, a biochemical process that strengthens the mucus layer and enhances its protective capacity. Consequently, the fortified barrier prevents the translocation of toxins and pathogens into the deeper layers of the intestinal tissue.
The study reveals that GLU operates through two distinct pathways: one dependent on the gut microbiota and one independent of it. In the microbiota-dependent pathway, GLU increases the abundance of the probiotic Lactobacillus amylovorus. This bacterium produces indole-3-acetic acid (IAA), which acts as a ligand for the aryl hydrocarbon receptor (AHR). Furthermore, GLU can directly activate AHR in a microbiota-independent manner. This dual activation is crucial for maintaining intestinal homeostasis under toxic stress.
Once activated, AHR transcriptionally up-regulates the expression of the sulfotransferase GAL3ST3. This enzyme is the primary driver behind the enhanced mucin sulfation observed in the study. Moreover, the increased sulfation level directly correlates with reduced inflammation and improved tissue recovery. Therefore, targeting the AHR-GAL3ST3 axis through nutritional interventions like GLU could represent a breakthrough in managing environmental toxin exposure.
Mucin sulfation is essential for protecting the gut lining from enzymatic degradation and toxic insults. By increasing the negative charge of the mucus, it creates a more resilient shield against common dietary toxins like deoxynivalenol.
Glucuronolactone promotes the growth of beneficial bacteria such as Lactobacillus amylovorus. These probiotics produce metabolites like indole-3-acetic acid, which then signal the host's immune system to strengthen the intestinal barrier.
While the primary study used piglet models, the conserved nature of the AHR pathway and mucin regulation suggests that GLU may serve as an effective nutritional supplement for humans exposed to mycotoxin-contaminated grains.
Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. Always seek the guidance of a qualified healthcare professional regarding any medical condition or treatment. Refer to the latest local and national guidelines for clinical practice.
References
Cui C et al. Glucuronolactone Promotes Mucin Sulfation to Alleviate Deoxynivalenol-Induced Intestinal Injury via Microbiota-Dependent and -Independent AHR Activation. Adv Sci (Weinh). 2026 Feb 23. doi: 10.1002/advs.202522912. PMID: 41725587.
Wan ML et al. Deoxynivalenol modulated mucin expression and proinflammatory cytokine production, affecting susceptibility to enteroinvasive Escherichia coli infection in intestinal epithelial cells. PMC. 2025.
Ji T et al. Indole-3-Acetic Acid Alters Intestinal Microbiota and Alleviates Ankylosing Spondylitis in Mice. Front Immunol. 2025.

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


New research identifies glucuronolactone as a key protector of the intestinal barrier against DON mycotoxins through AHR-mediated mucin sulfation....
6 months ago

Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today

A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today

Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today

Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday

The All-India Food Processors' Association has approached the Supreme Court to oppose FSSAI's proposed per-100g benchmark for front-of-pack warning labels, advocating instead for a per-serving threshold. We explore the regulatory showdown, nutritional evidence, and implications for clinical lifestyle counseling.
Today